https://www.businesswire.com/news/home/20190424005327/en/

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Apr 24, 2019--Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced that it has received the 2019 Technology Innovation in Melanoma Award from the American Skin Association (ASA). Castle Biosciences was recognized for advancing innovative technology in the field of dermatology.

“We are honored to receive this award, which reflects our company’s foundational belief that bringing innovative molecular testing technology to underserved cancers can drive improvements in patient management,” said Derek Maetzold, Founder, President and CEO of Castle Biosciences. “Gene expression profile tests such as DecisionDx-Melanoma bring a new understanding of tumor biology that can result in more informed decision-making, optimized health outcomes and reduced healthcare costs compared to use of traditional clinical and pathologic factors alone.”